Refine
Has Fulltext
- yes (16)
Is part of the Bibliography
- yes (16)
Year of publication
Document Type
- Journal article (13)
- Doctoral Thesis (2)
- Working Paper (1)
Keywords
- ABCG2 (1)
- Anticoagulants (1)
- BCI (1)
- BRICS-Staaten (1)
- Behandlungsoption (1)
- Berger-Parker (1)
- Biomarker (1)
- CML (1)
- CVID (1)
- Chronic myeloid leukaemia (1)
- Coagulation factor IX (1)
- Coexpression (1)
- Coumarin (1)
- Diversity (1)
- EORTC-BN20 (1)
- EORTC-QLQ-C15-PAL (1)
- EZH1 (1)
- EZH2 (1)
- Einnähung (1)
- Emerging Power (1)
- European Society for Immunodeficiencies (ESID) (1)
- German PID-NET registry (1)
- H3K27me3 (1)
- Haematology (1)
- Hill's powers (1)
- Hinterkammerlinse (1)
- IOL (1)
- IgG substitution therapy (1)
- Imatinib (1)
- Indian Economy (1)
- Indien / Government (1)
- Indien / Parliament / House of the People (1)
- Inhibition (1)
- Insekt (1)
- Internationale Politik (1)
- Katarakt (1)
- Locomotion compensator (1)
- Molecularly targeted therapy (1)
- Multiples Myelom (1)
- Narendra Modi (1)
- Neisseria gonorrhoeae (1)
- PID prevalence (1)
- PTCL (1)
- Pan-Raf-Inhibition (1)
- Plasmozytom (1)
- Political Science (1)
- Prediction (1)
- Raf-Kinasen (1)
- Risk factors (1)
- Säkularismus (1)
- T-cell non-Hodgkin's lymphomas (1)
- Translational research (1)
- VKORC1 (1)
- Verhalten (1)
- Vitamin K epoxide reductase (1)
- Warfarin (1)
- Ziliarsulkus (1)
- arbuscular mycorrhizal fungi (1)
- arthropods (1)
- bioassay-guided fractionation (1)
- biodiversity (1)
- brain tumours (1)
- breast cancer (1)
- cancer patients (1)
- chemical diversity (1)
- chronic myeloid leukemia (1)
- clinical trials (1)
- communication systems (1)
- different imatinib dose regimens (1)
- early applied higher imatinib dosages (1)
- epigenetics (1)
- global (1)
- host recognition (1)
- immunohistochemistry (1)
- lung cancer (1)
- molecular diversity (1)
- motor imagery technology (1)
- next generation sequencing (1)
- older patients (1)
- olfactometer (1)
- partitioning analysis RPA (1)
- plant diversity (1)
- plantago lanceolata (1)
- primary immunodeficiency (PID) (1)
- prognostic index (1)
- radiation oncology (1)
- registry for primary immunodeficiency (1)
- shannon index (1)
- simpson's index (1)
- single-trial EEG classification (1)
- spatial (1)
- spatial filters movement (1)
- species richness (1)
- stem arena (1)
- survival (1)
- symptoms (1)
- temporal (1)
- turnover (1)
- validation (1)
- whole-brain radiotherapy (1)
- xxx (1)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (6)
- Medizinische Klinik und Poliklinik II (5)
- Augenklinik und Poliklinik (1)
- Institut für Humangenetik (1)
- Institut für Politikwissenschaft und Soziologie (1)
- Institut für Psychologie (1)
- Kinderklinik und Poliklinik (1)
- Klinik und Poliklinik für Strahlentherapie (1)
- Pathologisches Institut (1)
Sonstige beteiligte Institutionen
Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs.
Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel.
Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1-25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57% of all 2,453 PID patients (including 728 CVID patients). A gene defect was identified in 36% of patients. Familial cases were observed in 21% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0-88 years). Presenting symptoms comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, no PID had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE-syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49% of all patients received immunoglobulin G (IgG) substitution (70%-subcutaneous; 29%-intravenous; 1%-unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy.
Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment.
The impact of imatinib dose on response rates and survival in older patients with chronic myeloid leukemia in chronic phase has not been studied well. We analyzed data from the German CML-Study IV, a randomized five-arm treatment optimization study in newly diagnosed BCR-ABL-positive chronic myeloid leukemia in chronic phase. Patients randomized to imatinib 400 mg/day (IM400) or imatinib 800 mg/day (IM800) and stratified according to age (≥65 years vs. <65 years) were compared regarding dose, response, adverse events, rates of progression, and survival. The full 800 mg dose was given after a 6-week run-in period with imatinib 400 mg/day. The dose could then be reduced according to tolerability. A total of 828 patients were randomized to IM400 or IM800. Seven hundred eighty-four patients were evaluable (IM400, 382; IM800, 402). One hundred ten patients (29 %) on IM400 and 83 (21 %) on IM800 were ≥65 years. The median dose per day was lower for patients ≥65 years on IM800, with the highest median dose in the first year (466 mg/day for patients ≥65 years vs. 630 mg/day for patients <65 years). Older patients on IM800 achieved major molecular remission and deep molecular remission as fast as younger patients, in contrast to standard dose imatinib with which older patients achieved remissions much later than younger patients. Grades 3 and 4 adverse events were similar in both age groups. Five-year relative survival for older patients was comparable to that of younger patients. We suggest that the optimal dose for older patients is higher than 400 mg/day. ClinicalTrials.gov identifier: NCT00055874
Background
VKORC1 has been identified some years ago as the gene encoding vitamin K epoxide reductase (VKOR) – the target protein for coumarin derivates like warfarin or phenprocoumon. Resistance against warfarin and other coumarin-type anticoagulants has been frequently reported over the last 50 years in rodents due to problems in pest control as well as in thrombophilic patients showing variable response to anticoagulant treatment. Many different mutations have already been detected in the VKORC1 gene leading to warfarin resistance in rats, mice and in humans. Since the conventional in vitro dithiothreitol (DTT)-driven VKOR enzymatic assay often did not reflect the in vivo status concerning warfarin resistance, we recently developed a cell culture-based method for coexpression of VKORC1 with coagulation factor IX and subsequent measurement of secreted FIX in order to test warfarin inhibition in wild-type and mutated VKORC1.
Results
In the present study, we coexpressed wild-type factor IX with 12 different VKORC1 variants which were previously detected in warfarin resistant rats and mice. The results show that amino acid substitutions in VKORC1 maintain VKOR activity and are associated with warfarin resistance. When we projected in silico the amino acid substitutions onto the published three-dimensional model of the bacterial VKOR enzyme, the predicted effects matched well the catalytic mechanism proposed for the bacterial enzyme.
Conclusions
The established cell-based system for coexpression of VKORC1 and factor IX uses FIX activity as an indicator of carboxylation efficiency. This system reflects the warfarin resistance status of VKORC1 mutations from anticoagulant resistant rodents more closely than the traditional DTT-driven enzyme assay. All mutations studied were also predicted to be involved in the reaction mechanism.
T-cell lymphomas are highly heterogeneous and their prognosis is poor under the currently available therapies. Enhancers of zeste homologue 1 and 2 (EZH1/2) are histone H3 lysine-27 trimethyltransferases (H3K27me3). Despite the rapid development of new drugs inhibiting EZH2 and/or EZH1, the molecular interplay of these proteins and the impact on disease progression and prognosis of patients with T-cell lymphomas remains insufficiently understood. In this study, EZH1/2 mutation status was evaluated in 33 monomorphic epitheliotropic intestinal T-cell lymphomas by next generation sequencing and EZH1/2 and H3K27me3 protein expression levels were detected by immunohistochemistry in 46 T-cell lymphomas. Correlations with clinicopathologic features were analyzed and survival curves generated. No EZH1 mutations and one (3%) EZH2 missense mutation were identified. In univariable analysis, high EZH1 expression was associated with an improved overall survival (OS) and progression-free survival (PFS) whereas high EZH2 and H3K27me3 expression were associated with poorer OS and PFS. Multivariable analysis revealed EZH1 (hazard ratio (HR) = 0.183; 95% confidence interval (CI): 0.044–0.767; p = 0.020;) and EZH2 (HR = 8.245; 95% CI: 1.898–35.826; p = 0.005) to be independent, divergent prognostic markers for OS. In conclusion, EZH1/2 protein expression had opposing effects on the prognosis of T-cell lymphoma patients.
The importance of olfactory versus contact cues for host plant recognition was investigated in the tortoise beetle Cassida canaliculata Laich. (Coleoptera: Chrysomelidae), which is strictly monophagous on meadow sage. The reaction of adult beetles to olfactory and contact host cues was tested using three bioassays (locomotion compensator, six-chamber-olfactometer, stem arena') to account for different behavioral contexts. Bioassay-guided fractionation of plant extracts was elaborated to characterize the nature of contact stimuli. The beetles were only slightly attracted to odors from small amounts of leaf material. However, when contact cues were provided additionally, the beetles showed strong preferences for samples of their host plant over controls. Bioassay-guided fractionation led to isolation of at least two non-polar contact stimuli acting in concert that are sufficient for host plant identification in C. canaliculata.
Das Multiple Myelom (MM) ist eine durch monoklonale Vermehrung terminal differenzierter Antikörper-produzierender B-Lymphozyten (Plasmazellen) im Knochenmark charakterisierte maligne Krankheit, die sich v.a. in osteolytischen Knochendestruktionen, hämatopoetischer und Niereninsuffizienz äußert. Verbesserte Therapieansätze wie die Hochdosis-Chemotherapie mit Melphalan und anschließender autologer Stammzelltransplantation sowie die Einführung neuer pharmakologischer Substanzklassen (Proteasom-Inhibitoren, Cereblon-bindende Thalidomidderivate) führten zu einer Verlängerung der durchschnittlichen Überlebenszeit, für die meisten der Patienten ist die Erkrankung jedoch derzeit unheilbar. Die Erforschung neuer potenzieller therapeutischer Angriffspunkte auf Grund pathobiologischer Erkenntnisse bleibt daher unabdingbar. Ein Ansatz zur Verbesserung des Verständnisses der Pathogenese ist die funktionelle, molekulare und genetische Analyse des Signalnetzwerkes im MM. Im Zusammenhang mit diesem Konzept wurde entdeckt, dass wachstums-regulierende Signalwege in MM Zellen aktiviert oder dereguliert sind und zum Überleben und der Proliferation des Tumors beitragen. So konnte beispielsweise von unserer Arbeitsgruppe bereits gezeigt werden, dass onkogenes Ras essentiell zum Überleben der MM Zellen beiträgt. Da Ras derzeit mangels spezifischer Inhibitoren pharmakologisch nicht angreifbar ist, stellen weitere funktionelle Bestandteile des Signalweges eine potenzielle therapeutische Zielstruktur dar. Während die Blockade von MEK1/2 in MM Zellen keinen Einfluss auf das Überleben hatte, konnte durch die Blockade von Raf in ersten Tests unserer Arbeitsgruppe Apoptose hervorgerufen werden. Aus diesem Grund habe ich in der vorliegenden Arbeit zur Evaluation eines neuen Therapieansatzes die Rolle der Raf-abhängigen Signaltransduktion eingehend untersucht. Als Grundlage diente dabei die Hypothese, dass die Raf-Kinasen entscheidende Effektoren der durch onkogenes Ras vermittelten apoptotischen Effekte darstellen. In einem ersten Schritt konnte ich nachweisen, dass alle drei Raf-Isoformen (A-, B- und C-Raf) in humanen MM Zelllinien und in primären MM Zellen aktiviert sind. Mittels shRNA-vermittelter, Isoform-spezifischer Raf-Knockdown-Experimente konnte ich zeigen, dass nur ein simultaner Knockdown aller Isoformen, d.h. ein Pan-Raf-Knockdown, zu einer De-Phosphorylierung von MEK1/2 und ERK1/2 führte. Dieser Versuch ließ sich mittels pharmakologischer Raf-Inhibition, bei der ebenfalls nur eine Pan-Raf-Blockade zu einer Herunterregulation von MEK1/2 und ERK1/2 in MM Zellen führte, bestätigen. Das MEK/ERK-Modul stellte somit einen hervorragenden Surrogat- und Biomarker für die Pan-Raf-Aktivität dar. Im Gegensatz zur Blockade des MEK/ERK-Moduls führte eine Hemmung der Pan-Raf-Aktivität mittels shRNA oder pharmakologischer Inhibitoren in allen untersuchten Zelllinien und in der Mehrheit der primären MM Zellen zu einer starken Induktion von Apoptose. Da das Ansprechen auf eine Pan-Raf-Blockade nicht mit dem Ras-Mutationsstatus korrelierte, könnten die Raf-Kinasen eine von onkogenem Ras unabhängie Qualität als therapeutische Zielstruktur aufweisen. Zur Untersuchung möglicher MEK/ERK-unabhängiger Effektormechanismen der Pan-Raf-Inhibition habe ich die mRNA-basierten Genexpressionsprofile von INA-6 Zellen nach pharmakologischer Pan-Raf- oder MEK-Inhibition verglichen. Dabei führte die Pan-Raf-Inhibition zu einer Regulation von wesentlich mehr Genen, wobei sich auch die Art der regulierten Gene unterschied, darunter Gene mit tumorrelevanten Funktionen wie Regulation von Proliferation, Zellzyklus und Apoptose. Für eine dieser Gengruppen, die Gruppe der PI3K-abhängigen, mTOR-assoziierten Gene, konnte ich eine Regulation auch auf der Proteinebene nachweisen: die Phosphorylierungen von mTOR, p70S6K, Rb und AKT und die Expression von CyclinD1 und PDK1 waren nach Pan-Raf-Inhibition, nicht jedoch nach MEK-Blockade herunterreguliert. Dieses Ergebnis deutet auf eine Ko-Regulation der PI3K-abhängigen Signaltransduktion durch die Raf-kinasen hin. Mittels spezifischer PI3K-Inhibitoren ließ sich sowohl bei der Regulation der untersuchten Proteine als auch bei der Induktion von Apoptose eine deutliche Verstärkung der Pan-Raf-Inhibition in HMZL und in primären Zellen erzielen. Zusammengefasst zeigt diese Arbeit, dass die Pan-Raf-Blockade eine neue Therapiemöglichkeit darstellt, die durch Kombination mit einer PI3K/AKT-Inhibition noch verstärkt werden kann.
India's economic rise since the 1990s has been followed by a more prominent global role for the country. Despite economic setbacks in recent years and huge domestic challenges like poverty, caste issues, and gender inequality, India today is almost universally characterised as an “emerging power”. At the same time, the country continues to show an enormous diversity. Thus, exploring emerging India can surely not be confined to economic analysis only. Instead, it is vital to take current developments in domestic and international politics, society, culture, religion, and political thinking into consideration as well. Following an interdisciplinary approach, contributions from Political Science, International Relations, Indology, Political Theory, and Economics are fundamental in order to grasp the country's diversity. This collection assembles eight essays which, individually, serve as working papers reflecting the authors' various research focuses, while collectively composing a multifaceted and multidis-ciplinary picture of emerging India. It thereby reflects the approach the University of Würz-burg’s Centre for Modern India and the Institute for Political Science and Sociology’s India Forum are committed to: bringing together different academic disciplines in order to generate nuanced insights into India’s manifold diversity.
Background: Recently published results of quality of life (QoL) studies indicated different outcomes of palliative radiotherapy for brain metastases. This prospective multi-center QoL study of patients with brain metastases was designed to investigate which QoL domains improve or worsen after palliative radiotherapy and which might provide prognostic information.
Methods: From 01/2007-01/2009, n=151 patients with previously untreated brain metastases were recruited at 14 centers in Germany and Austria. Most patients (82 %) received whole-brain radiotherapy. QoL was measured with the EORTC-QLQ-C15-PAL and brain module BN20 before the start of radiotherapy and after 3 months.
Results: At 3 months, 88/142 (62 %) survived. Nine patients were not able to be followed up. 62 patients (70.5 % of 3-month survivors) completed the second set of questionnaires. Three months after the start of radiotherapy QoL deteriorated significantly in the areas of global QoL, physical function, fatigue, nausea, pain, appetite loss, hair loss, drowsiness, motor dysfunction, communication deficit and weakness of legs. Although the use of corticosteroid at 3 months could be reduced compared to pre-treatment (63 % vs. 37 %), the score for headaches remained stable. Initial QoL at the start of treatment was better in those alive than in those deceased at 3 months, significantly for physical function, motor dysfunction and the symptom scales fatigue, pain, appetite loss and weakness of legs. In a multivariate model, lower Karnofsky performance score, higher age and higher pain ratings before radiotherapy were prognostic of 3-month survival.
Conclusions: Moderate deterioration in several QoL domains was predominantly observed three months after start of palliative radiotherapy for brain metastases. Future studies will need to address the individual subjective benefit or burden from such treatment. Baseline QoL scores before palliative radiotherapy for brain metastases may contain prognostic information.
Despite therapeutic advances multiple myeloma remains largely incurable, and novel therapeutic concepts are needed. The Hsp90-chaperone is a reasonable therapeutic target, because it maintains oncogenic signaling of multiple deregulated pathways. However, in contrast to promising pre-clinical results, only limited clinical efficacy has been achieved through pharmacological Hsp90 inhibition. Because Hsp70 has been described to interact functionally with the Hsp90-complex, we analyzed the suitability of Hsp72 and Hsp73 as potential additional target sites. Expression of Hsp72 and Hsp73 in myeloma cells was analyzed by immunohistochemical staining and western blotting. Short interfering RNA-mediated knockdown or pharmacological inhibition of Hsp72 and Hsp73 was performed to evaluate the role of these proteins in myeloma cell survival and for Hsp90-chaperone function. Furthermore, the role of PI3K-dependent signaling in constitutive and inducible Hsp70 expression was investigated using short interfering RNA-mediated and pharmacological PI3K inhibition. Hsp72 and Hsp73 were frequently overexpressed in multiple myeloma. Knockdown of Hsp72 and/or Hsp73 or treatment with VER-155008 induced apoptosis of myeloma cells. Hsp72/Hsp73 inhibition decreased protein levels of Hsp90-chaperone clients affecting multiple oncogenic signaling pathways, and acted synergistically with the Hsp90 inhibitor NVP-AUY922 in the induction of death of myeloma cells. Inhibition of the PI3K/Akt/GSK3b pathway with short interfering RNA or PI103 decreased expression of the heat shock transcription factor 1 and down-regulated constitutive and inducible Hsp70 expression. Treatment of myeloma cells with a combination of NVP-AUY922 and PI103 resulted in additive to synergistic cytotoxicity. In conclusion, Hsp72 and Hsp73 sustain Hsp90-haperone function and critically contribute to the survival of myeloma cells. Translation of Hsp70 inhibition into the clinic is therefore highly desirable. Treatment with PI3K inhibitors might represent an alternative therapeutic strategy to target Hsp70.
Die transsklerale Einnähung von Hinterkammerlinsen ist heutzutage eine etablierte Operationstechnik zur funktionellen Rehabilitation von Augen mit teilweise beschädigtem oder gänzlich fehlendem Kapselhalteapparat. In der vorgestellten Studie wurden die Akten von 65 Patienten retrospektiv ausgewertet, denen von einem Operateur im Zeitraum von April 1996 bis März 2004 eine HKL nach der modifizierten Methode von Mittelviefhaus und Wiek transskleral eingenäht wurde. 39 (60%) der Patienten waren männlich und 26 (40%) weiblich. Der Altersdurchschnitt betrug 64,9 Jahre (9-90 Jahre). Der Großteil der Augen war voroperiert und hatte einen oder mehrere zusätzliche pathologische Befunde. 36 der Patienten waren vor dem Eingriff pseudophak, 21 waren aphak und 8 waren phak. Der Eingriff dauerte bei den 65 Patienten im Mittel 70,4 ± 18,0 Minuten (38-136 Minuten). Die Nachuntersuchungen erfolgten 6 Wochen, 24 Wochen, 52 Wochen und 3 Jahre nach der Operation. Die mitt-lere Nachbeobachtungsdauer betrug 20 Monate (0-3,4 Jahre). Nach 6 Wochen erschie-nen 59 Patienten, nach 24 und 52 Wochen jeweils 44 Patienten und nach 3 Jahren noch 33 Patienten zur Nachuntersuchung. Wie die Ergebnisse zeigten, betrug die Refraktionsabweichung nach einem Jahr im Mit-tel 1,73 dpt. Innerhalb ± 2 dpt befanden sich 61,76% der Patienten und innerhalb ± 1 dpt 29,41% der Patienten. Nach 3 Jahren lag die Refraktionsabweichung im Mittel bei 1,82 dpt. 60% befanden sich innerhalb ± 2 dpt und 36% innerhalb ± 1 dpt. Die Refraktionsaberration zeigte eine deutlich myope Tendenz, denn bei den jeweiligen Untersuchungen waren 65%, 74% und 72% der Werte myoper als die berechnete Zielrefraktion. Der präoperative Durchschnittsvisus betrug 0,27, nach 3 Jahren lag er bei 0,33. Nach 3 Jahren waren bei 52% der erschienenen Patienten die Visuswerte besser, bei 39% schlechter und bei 9% unverändert im Vergleich zu den präoperativ ermittelten Werten. Insgesamt fand eine leichte Visusverbesserung statt. Postoperativ unerwünschte Befunde stellten 3 zystoide Makulaödeme (2 nach 6 Wo-chen, 1 nach einem Jahr) und 3 Netzhautablösungen (2 nach 6 Wochen, 1 nach 3 Jah-ren) dar. Von den beiden nach 6 Wochen aufgetretenen zystoiden Makulaödemen konnte eines behandelt werden, der andere Patient erschien zu keiner weiteren Untersuchung. Das Ödem, das nach einem Jahr aufgetreten war, resorbierte von selbst. Die beiden nach 6 Wochen aufgetretenen Ablationes wurden mit einer Cerclage wieder zum Anliegen gebracht, der andere Patient mit Ablatio erschien zu keiner der weiteren Untersuchungen. Bei zwei Patienten musste ein weiterer Eingriff erfolgen, jedoch nicht unmittelbar aus Gründen der HKL-Einnähung. Postoperativ ereigneten sich keine Linsendislokationen. Die Ergebnisse unserer Arbeit bezüglich des postoperativen Visusverlaufs, der Refraktionsaberration, des Auftretens von Netzhautpathologien und HKL-Dislokation bewegen sich innerhalb der in der Literatur angegebenen Häufigkeiten. Man sollte dabei allerdings berücksichtigen, dass unterschiedliche Studienbedingungen und Patientengüter ebenso wie differierende Untersuchungszeiträume die Grundlage für eine absolute Ver-gleichbarkeit entziehen.